GXV813, GXV813, Placebo 0 mg Hard gelatin capsule
CGXV813B12201
Phase 2 small_molecule active
Quick answer
GXV813, GXV813, Placebo 0 mg Hard gelatin capsule for Schizophrenia is a Phase 2 program (small_molecule) at Novartis Ophthalmics Europe with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novartis Ophthalmics Europe
- Indication
- Schizophrenia
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active